A. G. Cudós

Metabolic synthetic lethality: a randomized, phase 0/I trial of the mitochondrial inhibitor ME-344 or placebo added to bevacizumab in early HER2-negative breast cancer.

Gion, S. Morales, J. Cortés, 2019 .

1944 Pathological complete response (pCR) after neoadjuvant chemotherapy in luminal breast cancer

A. G. Cudós, S. M. Murillo, F. V. Villellas, 2015 .

Survival analysis of bevacizumab plus taxane treatment in luminal metastatic breast cancer

A. G. Cudós, S. M. Murillo, F. V. Villellas, 2021, Future science OA.